Analysis on laryngopharyngeal lesions of patients with acquired immune deficiency syndrome

doi:10.3877/cma.j.issn.1674-1358.2019.03.005

Abstract

Abstract:

Objective

To investigate the clinical characteristics of laryngopharyngeal diseases of patients with acquired immune deficiency syndrome (AIDS).

Methods

Data of 82 patients with AIDS who were complicated with laryngopharyngeal diseases and locally positive signs in Department of Otolaryngology, Beijing Ditan Hospital, Capital Medical University from January 2009 to October 2018 were collected. The clinical characteristics of laryngopharyngeal diseases of these cases were analyzed and summarized.

Results

There were 33 cases with ulcer manifestations, which developed mainly at multiple sites (10 cases), and following by tonsil (5 cases), posterior pharyngeal wall (4 cases), palatopharyngeal arch (3 cases), palatoglossal arch (3 cases), ateral pharyngeal wall (2 cases), epiglottis (2 cases), soft palate (1 case), lingual root (1 case), vocal cord (1 case) and splitting (1 case). There were 21 cases with acute and chronic congestion and swelling in pharynx and larynx and 13 cases with white fungus moss attachment. There were 7 cases with new biological manifestations, including 4 cases with Kaposi’s sarcoma (KS) and 3 cases with papilloma. There were 7 cases with vocal cord paralysis, including 6 cases with hoarseness and 1 case with dysphagia. One case were found tonsillar grade Ⅲ enlargement due to immune reconstruction. Among the 82 patients, 79 patients were treated with systemic highly active antiroviral therapy (HAART) or local targeted treatment of throat diseases, 69 of whom were treated with systemic HAART and 68 cases were given local targeted treatment; while 3 patients without systemic HAART or local treatment. Results of 79 patients with treatment were 61 cases with effective, 14 cases with ineffective and 4 cases died. Three cases without systemic or local treatment did not get better.

Conclusions

The laryngopharyngeal diseases of AIDS patients are mainly ulcer, which has a long course, with severe symptoms, easy recurrence, difficult to cure and related to basic diseases; besides ulcerative diseases, opportunistic infections and tumors could also be found. Treatment of such diseases is mainly to improve the immune status, supplemented by symptomatic treatment.

Key words: Acquired immune deficiency syndrome, Laryngopharyngeal diseases

Lisong Zhang, Hongxin Zhao, Gaoli Fang, Jing Hou, Aimin Ma. Analysis on laryngopharyngeal lesions of patients with acquired immune deficiency syndrome[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2019, 13(03): 196-201.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2019.03.005

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2019/V13/I03/196

Figures/Tables 4

References 23

[1]	Barzan L, Tavio U, Comorett R. Head and neck manifestation during HIV infection[J]. J Laryngol Otol,1993,107(2):133-136.
[2]	卢永德. AIDS在耳鼻咽喉-头颈部的表现[J]. 国外医学耳册,1995,19(3):142-144.
[3]	薛明学, 黄祖仁, 乔宁生. HIV感染阳性104例在耳鼻咽喉-头颈部的表现[J]. 中国耳鼻咽喉颅底外科杂志,2001,7(2):117-118.
[4]	中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(第三版)[J]. 中华传染病杂志,2015,33(10):577-593.
[5]	Kanno T, Sato Y, Nakamura T, et al. Genotypic and clinicopathological characterization of Kaposi’s sarcoma-associated herpesvirus infection in Japan[J]. J Med Virol,2010,82(3):400-406.
[6]	李瑞玉, 林吉生, 江淑萍. 89例HIV阳性青年人咽部临床观察[J]. 耳鼻咽喉-头颈外科,2001,8(2):119-120.
[7]	房高丽, 张罗, 王成硕, 等. 艾滋病患者咽部溃疡病变特点分析[J]. 中华耳鼻咽喉头颈外科杂志,2014,49(2):125-130.
[8]	Macphail LA, Greenspan D, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection: diagnosis and treatement[J]. Oral Surg Oral Med Oral Pathlo,1992,73(3):283-288.
[9]	Chaudhry R, Akhtar S, Lucente FE, et al. Large oral ulcers leading to the destruction of the tonsils in patients with AIDS[J]. Otolaryngol Head Neck Surg,1996,114(3):474-478.
[10]	Paterson DL, Georghiou PR, Allworth AM, et al. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection[J]. Clin Infect Dis,1995,20(2):250-254.
[11]	徐光, 周文学. 艾滋病儿童耳鼻咽喉科疾患的诊治体会[J]. 中华耳鼻咽喉科杂志,1998,33(4):33-251.
[12]	Brahim JS, Roberts MW. Oral manifestations of human immunodeficiency virus infection[J]. Ear Nose Throat J,1990,69(3):446-474.
[13]	柳生, 廖光付. 29例AIDS患者咽拭子真菌培养报告[J]. 医学信息,2006,19(7):1238-1239.
[14]	Liu Z, Fang Q, Zuo J, et al. The world-wide incidence of Kaposi’s sarcoma in the HIV/AIDS era[J]. HIV Med,2018,19(5):355-364.
[15]	伍国伟, 莫辉. 免疫缺陷相关性卡波西肉瘤的研究进展[J]. 临床医学研究与实践,2016,1(13):192-193.
[16]	Hoffmann C, Sabranski M, Esser S. HIV-associated Kaposi’s sarcoma[J]. Oncol Res Treat,2017,40(3):94-98.
[17]	张莉, 裴园丽, 艾力·吐尔逊, 等. 25例卡波西肉瘤临床分析[J]. 现代肿瘤医学,2009,17(5):944-946.
[18]	Bibas M, Antinori A. EBV and HIV-related lymphoma[J]. Mediterr J Hematol Infect Dis,2009,1(2):e2009032.
[19]	Levine AM. AIDS-related lymphoma[J]. Semin Oncol Nurs,2006,22(2):80-89.
[20]	潘云, 李正金. 人免疫缺陷病毒感染获得性免疫缺陷综合征相关淋巴瘤[J]. 中华病理学杂志,2012,41(6):421-424.
[21]	Etemad-Moghadam S, Tirgary F, Keshavarz S, et al. Head and neck non-Hodgkin’S lymphoma:a 20-year demographic study of 381 cases[J]. Int J Oral Maxillofae Surg,2010,39(9):869-872.
[22]	Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK[J]. Haematologica,2009,94(6):875-880.
[23]	Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeftciency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy[J]. Blood,2000,96(8):2730-2734.

指标		例数（%）
性别		?
?	男	72（87.8）
?	女	10（12.2）
传播途径		?
?	性传播	35（42.7）
?	血液传播	9（11.0）
?	吸毒	1（1.2）
?	不详	37（45.1）
CD4⁺T淋巴细胞		?
?	<200个/μl	66（80.5）
?	>200个/μl	16（19.5）
CD4⁺/CD8⁺ T		?
?	<0.5	73（89.0）
?	>0.5	9（11.6）
HAART治疗		?
?	是	79（96.3）
?	否	3（3.7）

指标		例数（%）
性别		?
?	男	72（87.8）
?	女	10（12.2）
传播途径		?
?	性传播	35（42.7）
?	血液传播	9（11.0）
?	吸毒	1（1.2）
?	不详	37（45.1）
CD4⁺T淋巴细胞		?
?	<200个/μl	66（80.5）
?	>200个/μl	16（19.5）
CD4⁺/CD8⁺ T		?
?	<0.5	73（89.0）
?	>0.5	9（11.6）
HAART治疗		?
?	是	79（96.3）
?	否	3（3.7）

系统机会性感染	例数（%）
肺部感染	44（53.7）
口腔念珠菌感染	24（29.3）
CMV感染	22（26.8）
PCP感染	20（24.4）
肺结核	15（18.3）
深部真菌感染	15（18.3）
鹅口疮	14（17.1）
淋巴结结核	10（12.2）
疱疹病毒感染	8（9.8）
EB病毒感染	8（9.8）
恶性肿瘤	5（6.1）
淋巴瘤	3（3.7）
中枢神经系统感染	3（3.7）
MAC感染	1（1.2）
马尔尼菲蓝状菌感染	1（1.2）
嗜麦芽寡单胞菌肺炎	1（1.2）
弓形虫脑病	1（1.2）
隐球菌感染	1（1.2）

系统机会性感染	例数（%）
肺部感染	44（53.7）
口腔念珠菌感染	24（29.3）
CMV感染	22（26.8）
PCP感染	20（24.4）
肺结核	15（18.3）
深部真菌感染	15（18.3）
鹅口疮	14（17.1）
淋巴结结核	10（12.2）
疱疹病毒感染	8（9.8）
EB病毒感染	8（9.8）
恶性肿瘤	5（6.1）
淋巴瘤	3（3.7）
中枢神经系统感染	3（3.7）
MAC感染	1（1.2）
马尔尼菲蓝状菌感染	1（1.2）
嗜麦芽寡单胞菌肺炎	1（1.2）
弓形虫脑病	1（1.2）
隐球菌感染	1（1.2）

Please choose a citation manager

Content to export